Good Life Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Good Life Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,131	Closed	-$391K	–	389
2021 Q2	$391K	Sell	2,131 -7	-0.3%	-$1.2K	0.07%	195
2021 Q1	$325K	Buy	2,138 +129	+6%	+$20K	0.07%	212
2020 Q4	$315K	Sell	2,009 -118	-6%	-$15.2K	0.07%	185
2020 Q3	$241K	Buy	+2,127	New	+$229K	0.07%	200

Other funds holding ALXN

BCI

Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return

NICM

Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return

TAIM

TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return

CFO

CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return

MAM

Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Good Life Advisors's ALXN Position: Q3 2021 in Review

Good Life Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 2,131 shares — an estimated $391K sold.

Good Life Advisors first reported a position in ALXN in Q3 2020 and held it in 4 quarters. The position peaked at $391K in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

Good Life Advisors reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Good Life Advisors sold 2,131 Alexion Pharmaceuticals shares in Q3 2021, an estimated $391K.
Good Life Advisors first reported a position in Alexion Pharmaceuticals in Q3 2020 and held it in 4 quarters.
Good Life Advisors's Alexion Pharmaceuticals position peaked at $391K in Q2 2021.
7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Good Life Advisors's 13F filing for Q3 2021, filed 29 Oct 2021.